PharmiWeb

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the ...
PharmiWeb

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...
PharmiWeb

FluoGuide A/S Issue Warrants to Board Members, Executive Management and Employees

COPENHAGEN, DENMARK / ACCESS Newswire / November 3, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") announces that it has issued 199,000 warrants to members of the board directors, ...
PharmiWeb

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

POTOMAC, MARYLAND / ACCESS Newswire / November 3, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop ...
PharmiWeb

FluoGuide A/S Intends to Carry Out a Directed Share Issue of Approximately SEK 100 Million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER ...
PharmiWeb

Medical Care Technologies, Inc (OTC PINK:MDCE) Announces Development of AI-Powered Wellness App Suite with Global Reach

Generation Wellness to a Global Audience with Multilingual, Accessible AI Solutions MESA, ARIZONA / ACCESS Newswire / November 3, 2025 / Medical Care Technologies, Inc. (OTC Pink:MDCE) is excited to ...
PharmiWeb

CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / ...
PharmiWeb

Voters and researchers head to Parliament to see how politicians are using evidence

Voters and researchers head to Parliament to see how politicians are using evidenceThe public has made it clear that they expect MPs to look at the evidence when making decisions[1]. Following a ...
PharmiWeb

BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025

LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first ...
PharmiWeb

Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational ...
PharmiWeb

"Prejuvenation" Surge: Dr. Shervin Naderi Reveals How Millennials and Gen X Are Delaying Aging - Without Surgery

Dr. Naderi reveals how younger generations are embracing prejuvenation with collagen-boosting treatments and skincare to maintain a natural, youthful glow before aging signs appear. RESTON, VA / ...
PharmiWeb

The Assistance Fund Opens New Program for Macular Telangiectasia

Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Macular Telangiectasia ORLANDO, FL / ACCESS Newswire / November 3, 2025 / The Assistance Fund, an ...